OBR Daily Commentary

forumImage

Oncolytics Lung Cancer Drug Effective in Mid-Stage Trial, Shares Up

(Yahoo! News/Reuters) Mar 28, 2013 - Oncolytics Biotech Inc said its experimental lung cancer drug was found to be more effective in a mid-stage trial study, sending its shares up more than 10 percent.

Read Article arrow

H. Jack West, MD (Posted: March 28, 2013)

quotesThe numbers are small, but I agree that this early work is encouraging and justifies further studies. It's especially welcome to see promising work in patients with squamous cell NSCLC, who have fewer treatment options than those patients with non-squamous NSCLC.quotes

Add Comment 1 Comment
forumImage

Why Are Healthcare Costs Exploding? See Proton Cancer Therapy

(Xconomy) Mar 18, 2013 - Newer technology must always be better, right? Never mind if it costs a little extra.

Read Article arrow

H. Jack West, MD (Posted: March 18, 2013)

quotesI'm quoted in this article, which I think is really quite balanced and raises several very important points. Proton beam radiation is 3x more expensive than conventional radiation and is devoid of any compelling evidence that it improves outcomes significantly for any but the rarest cancers. We need to ensure that evidence and not marketing drive our treatments, and right now proton beam radiation is far too expensive to mislead the public into thinking it should be a clear standard of care for the vast majority of cancers. quotes

Add Comment 1 Comment
forumImage

Special Report: Behind a Cancer-Treatment Firm's Rosy Survival Claims

(Reuters) Mar 6, 2013 - When the local doctor who had been treating Vicky Hilborn told her that her rare cancer had spread throughout her body, including her brain, she and her husband refused to accept a death sentence. Within days, Keith Hilborn was on the phone with an "oncology information specialist" at Cancer Treatment Centers of America.

Read Article arrow

H. Jack West, MD (Posted: March 06, 2013)

quotesImportant piece that highlights the importance of aggressive marketing vs. actual data for cancer care. There is good reason to question the quality of the data highlighting better survival at CTCA, which may well be a product of selection bias if CTCA is cherry-picking which patients go into its analyses. In the article, it's noted by a fan of CTCA that "they market hope", and I agree...but it's not clear that this is really what should be marketed, especially if some or much of that is false hope.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...